4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow Doxercalciferol: new trials by email Literature Review of Doxercalciferol trials Research Report on Doxercalciferol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis Doxercalciferol, Placebo - Moderate to Severe Chronic Plaque Psoriasis | Phase 2 | Completed | Genzyme, a Sanofi Company | 111 | 2008-04-01 | 2014-05-05 |
| Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia doxercalciferol - Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | University of Wisconsin, Madison | 2002-09-01 | 2019-11-19 | |
| Doxercalciferol Before Surgery in Treating Localized Prostate Cancer doxercalciferol, conventional surgery - Prostate Cancer | Phase 2 | Completed | University of Wisconsin, Madison | 60 | 2001-08-01 | 2019-12-13 |
| Regulation of Bone Formation in Renal Osteodystrophy 1 alpha D2, 1,25 dihydroxy vitamin D3, Sevelamer HCl - Secondary Hyperparathyroidism, Renal Osteodystrophy | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 61 | 2000-11-01 | 2010-01-14 |
Chronic Kidney Disease-Mineral and Bone Disorder (1) · Hyperparathyroidism, Secondary (1) · Leukemia (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Prostatic Neoplasms (1) · Psoriasis (1)
University of Wisconsin, Madison (2) · Genzyme, a Sanofi Company (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)
United States (3)
George Wilding, MD (1) · Isidro B Salusky, MD (1) · Mark B. Juckett, MD (1)
P30CA014520 (2)